Specialty Pharma Industry Faces Tough Times; Wide-Moat Allergan Remains Our Top Pick
The specialty pharmaceuticals industry remains turbulent due to several industrywide headwinds--increasing customer buying power, more generic competition from a decline in the FDA backlog, fewer large patented drugs coming off patent, and rumors of collusion charges for some generic firms. In addition, the industry faces many company-specific self-inflicted wounds such as Valeant’s Philidor debacle, criticism of Mylan’s EpiPen price hikes, and Perrigo’s botched integration of Omega. With the ex...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.